Shares of Bioverativ Inc (NASDAQ:BIVV) gapped up before the market opened on Wednesday . The stock had previously closed at $51.30, but opened at $55.13. Bioverativ shares last traded at $59.03, with a volume of 2297200 shares changing hands.
Several analysts have recently weighed in on BIVV shares. Zacks Investment Research cut shares of Bioverativ from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 1st. Royal Bank of Canada started coverage on shares of Bioverativ in a research report on Thursday, September 14th. They set a “sector perform” rating and a $59.00 price objective on the stock. Deutsche Bank set a $53.00 price objective on shares of Bioverativ and gave the company a “hold” rating in a research report on Monday, November 20th. Piper Jaffray Companies restated an “overweight” rating and set a $71.00 price objective on shares of Bioverativ in a research report on Monday, October 23rd. Finally, Argus upgraded shares of Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 price objective on the stock in a research report on Wednesday, September 20th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Bioverativ has an average rating of “Hold” and an average price target of $60.47.
The company has a market capitalization of $6,360.00 and a PE ratio of 14.36.
Bioverativ (NASDAQ:BIVV) last issued its earnings results on Thursday, October 26th. The biotechnology company reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.25. The company had revenue of $291.60 million for the quarter, compared to analysts’ expectations of $285.45 million. Bioverativ had a net margin of 40.44% and a return on equity of 69.03%. The business’s revenue was up 27.2% on a year-over-year basis. equities research analysts anticipate that Bioverativ Inc will post 2.48 earnings per share for the current year.
A number of large investors have recently modified their holdings of the stock. Quotient Investors LLC bought a new stake in Bioverativ in the 3rd quarter worth $420,000. Mutual of America Capital Management LLC bought a new stake in Bioverativ in the 3rd quarter worth $5,062,000. Meeder Asset Management Inc. bought a new stake in Bioverativ in the 3rd quarter worth $877,000. Rockefeller Financial Services Inc. bought a new stake in Bioverativ in the 3rd quarter worth $1,480,000. Finally, State Treasurer State of Michigan bought a new stake in Bioverativ in the 3rd quarter worth $2,323,000. Institutional investors own 95.99% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Bioverativ (BIVV) Shares Gap Up to $55.13” was posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://transcriptdaily.com/2018/01/11/bioverativ-bivv-shares-gap-up-to-55-13.html.
Bioverativ Company Profile
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.